ACIS ResearchAI Civilization Investment ResearchContact AI BIOTECH · ARCHIVE
AI Biotech
AI drug platforms, clinical validation and pharma partnerships.
LATEST REPORT
Tempus Turns Data and Agent Tools Into Multi-Year Contracts, While Clinical Value Remains Unproven
AI Biotech Weekly | Issue 012
2026.10.28
FULL ARCHIVE
Find every published report
21 reports found
Tempus Turns Data and Agent Tools Into Multi-Year Contracts, While Clinical Value Remains Unproven
AI Biotech Weekly | Issue 012
AI Biotech Gains Human and Payment Validation, With Dilution and Small Samples Still Binding
AI Biotech Weekly | Issue 011
Pharma Starts Paying for Two Kinds of Biotech Evidence: Deliverable Platforms and Late-Stage-Ready Assets
Research Memo | METiS × Eli Lilly | Merck KGaA × Silence Therapeutics | AstraZeneca × Oracle | Tempus AI
Recursion Adds a First Sanofi Development-Candidate Option and Raises $200 Million as Validation and Dilution Arrive Together
Critical Event Update | Pharma Option × Human Signals × Equity Financing and Cash Runway
AI Biotech Wins Real Upfront Cash, but Human Efficacy Remains the Gate It Cannot Skip
AI Biotech Weekly | Issue 010
Zealand and Generate Sign an AI Protein Partnership Where the $30 Million Upfront Matters More Than the $1.2 Billion Headline
Critical Event Update | AI-Engineered Proteins × Obesity and Metabolic Disease × Revenue Quality
A $1.8 Billion Public-Private Push Turns Biological Data Into Core AI BioTech Infrastructure
Critical Event Update | Virtual Biology Initiative × Open Data × Predictive Cell Models
Catalysts Are Approaching, but Pivotal Human Evidence Has Not Arrived
AI Biotech Weekly | Issue 009
AI Diagnostics Is Productizing and Capital Is Returning, but Pivotal Human Proof Still Lags
AI Biotech Weekly | Issue 008
Tempus × Recursion: Data Moat Becomes Contracted — Not Yet a Cash Moat
AI Biotech Research Memo | Contract visibility improves; pricing power and cash conversion remain unproven | 24 September 2026
AI Biotech Puts Data Value Into Contracts, but Clinical and Cash Proof Still Lag
AI Biotech Weekly | Issue 007
Insilico Gains Commercial and Market Validation, but Clinical Proof Is Still the Next Gate
AI Biotech | Research Memo | 21 September 2026
Tempus Deepens Its Whole-Genome Data Moat, but Cash Conversion Remains Unproven
AI Biotech | Research Memo | Data-Asset Thesis Strengthened
Pharma Workflows and Medical Data Advance, but AI Biotech Still Needs Clinical and Cash Proof
AI Biotech Weekly | Issue 006
Rentosertib Shows a Human Signal: AI Drug Discovery Takes Another Step Toward Clinical Validation
Biotech | Research Memo | Thesis Strengthened
Novartis Pipeline Setbacks: Returning Biotech Capital Does Not Remove Clinical Risk
Biotech | Special Update | 10 September 2026
AI Designed Drugs Are Producing Human Evidence but Clinical Dispersion Is Widening
AI Biotech Weekly | Issue 005
Capital Is Back, but AI Drug Discovery Re-rates Only on Clinical Proof and Pharma Payment
AI Biotech Weekly | Issue 004
Biotech Capital Reflow Gains Further Confirmation
AI Biotech Weekly | Issue 003
Capital and Clinical Catalysts Are Converging
AI Biotech Weekly | Issue 002
From platform narratives to commercial and clinical proof
AI Biotech Weekly | Issue 001